Research programme: calcineurin modulators - Galenea/Otsuka Pharmaceutical

Drug Profile

Research programme: calcineurin modulators - Galenea/Otsuka Pharmaceutical

Latest Information Update: 01 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galenea
  • Class Small molecules
  • Mechanism of Action Calcineurin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Schizophrenia

Most Recent Events

  • 01 May 2012 Preclinical development is ongoing in the US
  • 30 Mar 2010 Preclinical development is ongoing in USA
  • 02 Dec 2009 Galenea and Ostuka Pharmaceutical further extend their research and development collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top